Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

13. april 2011 opdateret af: Bristol-Myers Squibb

A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects

The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF. This study also examines how long these drug combinations are effective in lowering viral load (level of HIV in the blood).

Studieoversigt

Undersøgelsestype

Interventionel

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35203
        • Sorra Research Ctr / Med Forum
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85016
        • Body Positive
    • California
      • Fresno, California, Forenede Stater, 93710
        • Hill Top Research Inc
      • Los Angeles, California, Forenede Stater, 900276069
        • Aids Healthcare Foundation
      • Los Angeles, California, Forenede Stater, 90024
        • UCLA Med Ctr / CARE BH-412 CHS
      • Los Angeles, California, Forenede Stater, 90073
        • West Los Angeles VAMC
      • Sherman Oaks, California, Forenede Stater, 91403
        • Sherman Oaks Hosp Research Institute
      • Torrance, California, Forenede Stater, 90502
        • Harbor UCLA Med Ctr / Research and Educational Institute
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06504
        • Yale New Haven Hosp / Nathan Smith Clinic
    • District of Columbia
      • Washington, District of Columbia, Forenede Stater, 20037
        • GW Med Ctr / Clinical Trials Unit
    • Florida
      • Fort Lauderdale, Florida, Forenede Stater, 33308
        • Med Alternatives
      • Fort Lauderdale, Florida, Forenede Stater, 33316
        • Urgent Care Ctr
      • Miami, Florida, Forenede Stater, 33142
        • Specialty Med Care Ctrs of South Florida Inc
      • Tampa, Florida, Forenede Stater, 33602
        • Hillsborough County Health Dept
      • Tampa, Florida, Forenede Stater, 33602
        • Saint Josephs Hosp
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern Univ / Div of Infect Diseases
      • Chicago, Illinois, Forenede Stater, 60612
        • Rush Presbyterian / ST Lukes Med Ctr
    • Kansas
      • Wichita, Kansas, Forenede Stater, 67214
        • Univ of Kansas School of Medicine / Office of Rsch
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 405360226
        • Ky Clinic Annex #4 / Room 205E / Speed Sort #0284
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater, 03756
        • Dartmouth-Hitchcock Med Ctr
    • New Jersey
      • Newark, New Jersey, Forenede Stater, 07103
        • NJCRI
      • Somerville, New Jersey, Forenede Stater, 08876
        • Infectious Disease Assoc of Central Jersey
    • New York
      • Farmingdale, New York, Forenede Stater, 11735
        • UCT International
      • New York, New York, Forenede Stater, 10011
        • St Luke Roosevelt Hosp
      • Rochester, New York, Forenede Stater, 14642
        • St Mary's Hosp (Univ of Rochester/Infectious Diseases)
      • Stony Brook, New York, Forenede Stater, 117948153
        • SUNY at Stony Brook / Div of Infectious Disease
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28207
        • Nalle Clinic / Clinical Research Dept
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74114
        • Associates in Med and Mental Health
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Stephen P Hauptman
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Med Univ of South Carolina / Div of Infect Disease
    • Texas
      • Galveston, Texas, Forenede Stater, 775550835
        • Univ of Texas / Med Branch at Galveston
      • Houston, Texas, Forenede Stater, 77004
        • Joseph C Gathe

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

Patients must have:

Within 15 business days prior to randomization:

  • CD4 cell count greater than or equal to 100 cells/mm3.
  • HIV RNA greater than or equal to 2,000 copies/ml by Roche Amplicor Assay.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

  • Bilateral peripheral neuropathy.
  • Intractable diarrhea.
  • Proven or suspected acute hepatitis within 30 days prior to study entry.

Concurrent Medication:

Excluded:

- Therapy for any co-existing disease that may interfere with patient ability to participate in this study.

Concurrent Treatment:

Excluded:

Therapy for any co-existing disease that may interfere with patient ability to participate in this study.

Patients with the following prior conditions are excluded:

History of acute or chronic pancreatitis.

Prior Medication:

Excluded:

  • Therapy for any previous disease that may interfere with patient ability to participate in this study.
  • Excluded within 14 days prior to randomization:

Greater than 4 weeks of nucleoside therapy or greater than 1 week of protease inhibitor therapy.

  • Excluded within 3 months of the start of this study or expected need at time of enrollment:
  • Agents with significant systemic myelosuppressive, neurotoxic, pancreatoxic, hepatotoxic, or cytotoxic potential.
  • Inability to tolerate oral medication.

Prior Treatment:

Excluded:

Therapy for any previous disease that may interfere with patient ability to participate in this study.

Risk Behavior:

Excluded:

Active alcohol or substance abuse that, in the opinion of the investigator, is sufficient to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 1998

Primær færdiggørelse (Faktiske)

1. september 1999

Studieafslutning (Faktiske)

1. september 1999

Datoer for studieregistrering

Først indsendt

2. november 1999

Først indsendt, der opfyldte QC-kriterier

30. august 2001

Først opslået (Skøn)

31. august 2001

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

25. april 2011

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. april 2011

Sidst verificeret

1. april 2011

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner